QIAGEN N.V. announced the launch of its next-generation automated nucleic acid purification platform, QIAsymphony Connect, at the AMP 2025 Annual Meeting in Boston, designed to support liquid biopsy applications and enhanced throughput, traceability and connectivity in laboratories. The new system builds on more than 3,000 placements of the first-generation version by end-2024 and is optimised for workflows such as minimal residual disease (MRD) monitoring with improved elution to maximise recovery, higher sample throughput (up to 50 % more in specific protocols), automated 2D barcode tracking and integration with laboratory information systems and QIAGEN’s cloud-based platform, QIA sphere. While full commercial release is scheduled for mid-2026, the system is already available via an early-access programme and the current version of QIAsymphony will continue to be offered during the transition period. “As labs face increasing pressure to process more complex samples with greater precision and speed, QIAsymphony Connect is designed to help them meet those challenges,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Our presence at AMP 2025 highlights our commitment to advancing high-growth areas of sample technologies where QIAGEN is playing a leading role in supporting customers worldwide with novel liquid biopsy applications as well as working with our partners to create innovative advances in precision oncology.”
Also Read: ArisGlobal Launches NavaX™ Agents Suite to Power Next-Gen Agentic AI in Life Sciences
In addition to the instrument launch, QIAGEN is showcasing a portfolio of precision oncology advancements within its “Sample to Insight” workflows, including early-access data from a joint workshop with Element Biosciences that demonstrates an efficient, scalable comprehensive genomic profiling (CGP) workflow for breast cancer FFPE samples using the QIAseq xHYB Trinity CGP on Element’s Trinity technology and QIAGEN’s bioinformatics tools, with commercial launch anticipated in early 2026. Concurrently, QIAGEN’s collaboration with Myriad Genetics Inc. features early-results from the QIAseq xHYB HRD Panel for research applications, showing high concordance with Myriad’s MyChoice ® CDx assay and enabling simultaneous analysis of 724 cancer-relevant genes including BRCA1/2, HRD, MSI and TMB a combined assay expected to move into full commercialisation (excluding Japan) in early 2026. These developments underscore QIAGEN’s strategy to deliver integrated automated solutions paired with advanced genomics and informatics to accelerate precision diagnostics in oncology.